The President & CEO of Five Prime Therapeutics is Exercising Options


Yesterday it was reported that the President & CEO of Five Prime Therapeutics (NASDAQ: FPRX), Aron Marc Knickerbocker, exercised options to buy 1,000 FPRX shares at $11.14 a share, for a total transaction value of $11.14K.

See today’s analyst top recommended stocks >>

Based on Five Prime Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $32.49 million and GAAP net loss of $20.39 million. In comparison, last year the company earned revenue of $7.82 million and had a GAAP net loss of $44.29 million. Currently, Five Prime Therapeutics has an average volume of 142.9K.

Nine different firms, including BMO Capital and Citigroup, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts